We acknowledge the traditional owners of country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to elders both past and present and all Aboriginal and Torres Strait Islander people, from whatever nation they may come. In particular, we acknowledge the Gadigal people of the Eora nation, and the people of the Kulin nation as the traditional owners of the lands and waters where our offices are located.

For Māori, the indigenous people of Aotearoa New Zealand we acknowledge Papatuanuku as our Earth Mother, and it is from her bond with Ranginui, the sky father, that we, and all the plants and creatures on earth, descend. From this whakapapa or lineage, we are connected by a common bond and for us as Māori this translates into an obligation as kaitiaki or guardians to care for and protect our land and resources and to maintain their life sustaining properties for the benefit of present and future generations.
About ANZGOG

The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is the peak national gynaecological cancer research organisation. We are recognised as a world leader in clinical trials research.

Our mission is to improve life for women with ovarian and other gynaecological cancers through research, cooperative clinical trials, information and awareness.

ANZGOG’s research has changed clinical practice both locally and globally. For more information please go to www.anzgog.org.au
Gynaecological Cancer

Gynaecological cancers originate in the female reproductive system. The main types of gynaecological cancers are ovarian, uterine, cervical and vulvar. Rarer types are vaginal cancer, fallopian tube cancer and placental cancer (which is pregnancy-related).

Every day in Australia, 17 women are diagnosed with a gynaecological cancer.

5.6 women will die from a gynaecological cancer today.

54% of women with ovarian cancer will not survive 5 years after diagnosis.

Women who carry a mutation in their BRCA1 or BRCA2 genes have an approximately 20% greater risk of developing ovarian cancer than women with normal BRCA genes. 20%

55% Endometrial cancer incidence has risen 55% in the last 10 years, partly due to the rise in obesity.

1 in 20 women risk being diagnosed with a gynaecological cancer by the age of 85.

Aboriginal and Torres Strait Islander women are 1.7x more likely to be diagnosed with gynaecological cancers – particularly uterine and cervical – than non-Indigenous women.

While survival across all cancers has improved by 19% over the past 25 years, the relative survival for all gynaecological cancers improved by just 7%.

"Virtually every advance in cancer has been made on the back of clinical trials."

Associate Professor Alison Brand

The highest incidence of all gynaecological cancers is found in remote and very remote areas, second only to major cities.

*Material sourced from Australian Institute of Health and Welfare
Dear Colleagues

The Annual Report gives me a chance to celebrate the many successes ANZGOG has had over the past year and thank the many people who have given generously of their time, energy and intellect to our organisation.

“I would like to recognise the contribution by Assoc Professor Alison Brand as Chair of ANZGOG over the past six years. During this time ANZGOG achieved financial stability and we strengthened both our culture of professional mentoring and leadership, increasing membership to almost 900 members. The annual trial portfolio increased significantly to more than 15 trials in development or recruiting patients.” Said Assoc Professor Philip Beale.

Clinical Trials – ANZGOG is committed to building a research portfolio and where required self-fund research. Our goals include a spectrum of trials – Phase III trials, Phase II trials, signal-seeking trials and early-phase trials where we are looking for new avenues of care, and also supportive care. It is important that we draw on all of the domains of gynaecological cancer care: surgery, radiation, nursing, allied health and medical oncology.

This is being achieved through a variety of initiatives:

OASIS (Ovarian cancer Alliance for Signal-seeking Studies) – this initiative to test new targeted therapies against molecular sub-types of ovarian cancer is a series of innovative signal-seeking Phase II studies. ANZGOG has been successful growing funding for this initiative from an initial philanthropic seed funding grant of $1.1million to now almost $11million. Six studies are either recruiting or in development.

Fund for New Research Grants – with the vision of fostering new research ideas which will eventuate in a clinical trial, this grants scheme is funded by public donations and awards up to $50,000 each to a maximum of three pilot or pre-clinical research projects each year. Since inception ANZGOG has funded six studies with a further three identified for funding in 2018.

Clinical Trials – Along with the six OASIS studies, ANZGOG has a further nine studies either recruiting or in development through its collaborations with the University of Sydney, NHMRC Clinical Trials Centre. These studies include ‘homegrown’ studies by ANZGOG investigators and international collaborations through the Gynecologic Cancer InterGroup with such countries as Canada, the United Kingdom and Italy. These studies also represent the multi-disciplinary nature of ANZGOG with surgical and exercise physiology clinical trials as well as immunotherapy and medical oncology treatments.

Funding for research – ANZGOG achieved funding in 2017-2018 year for the Stics and Stones study from NHMRC and funding and drug support for Solace 2 from Astra Zeneca.

In the last 5 years from 2013-2018 ANZGOG has had 1597 patients recruited across 16 studies. We are continuing to build our research portfolio to ensure more trials are available for patients, which hopefully means better care and better opportunities for treatment, but also further knowledge within the treatment of gynaecological cancers.

Translational ANZGOG – a significant initiative is TR-ANZGOG which addresses the critical need to collect biospecimens associated with clinical trials for research into biomarkers, molecular signatures, identification of therapeutic targets and other translational studies. After wide consultation we were able to secure funding and a Project Manager to start this initiative in 2018.

ANZGOG membership has more than doubled to 857 members in the last five years with members from all Australian States and Territories and all
parts of New Zealand. These members include clinicians, scientists, consumers, trial coordinators, nurses, data managers, exercise physiologists, health economists and biostatisticians.

We engage with them through our Annual Scientific Meeting in April, tumour working groups and our annual Research Development Day in November. We have a very active volunteer group within our membership with more than 100 members taking part in committees, workings groups, education sessions and other activities to mentor members and support our research.

**Strategic Goals** – ANZGOG reviewed its 2013-2018 Strategic Plan and defined its goals for the next five years through to 2023 in May 2019. These goals are:

**GOAL 1:** Innovative and equitable clinical trials in gynaecological cancers.

**GOAL 2:** World-class translational research in gynaecological cancers.

**GOAL 3:** Capacity building for gynaecological cancer research in Australia and New Zealand.

**GOAL 4:** Strategic partnerships, collaboration and engagement.

**GOAL 5:** Organisational capacity aligned with our research agenda.

We will continue to develop further maturity in our organisational capability and financial sustainability to support our gynaecological cancer research goals in an efficient and streamlined manner. This is supported through a range of activities not least of which is ANZGOG’s commitment to public fundraising and philanthropy.

**Thank you to our Supporters** - We have an outstanding array of supporters helping us raise funds for research and the conduct of clinical trials at hospitals. These include individual fundraisers, women sharing their stories in the media, on Facebook and our websites, companies and organisations that run events and fundraisers, thank you all.

I would like specifically to acknowledge the ongoing passion provided by Duncan McPherson, AM, and his tireless work with the Team Teal harness racing industry initiative #getrealsupportteal. Together with Michael Taranto over $495,000 has been raised for ANZGOG over the last 2 years.

Charlie Brown is another significant supporter of ANZGOG and has taken on the role of Ambassador at Large for ANZGOG and the ‘Save the Box’ fundraising initiative promoting awareness of gynaecological cancers and the need for further funding for research.

**Survivors Teaching Students** is another outstanding initiative. This volunteer program brings the faces and voices of ovarian cancer survivors and caregivers into the classrooms of health professional students to teach them about women’s experience with ovarian cancer diagnosis and treatment. Over 800 students were reached in year one of the program with 18 presentations to medical schools completed. The program is now rolling out across Australia. We thank the outstanding contribution by so many women and their families supporting this program.

Our people are our strength and I want to thank all ANZGOG members, staff and our supporters who have contributed to another successful year for clinical research in Australia and New Zealand.

“ANZGOG has achieved significant growth. In 2018 our annual portfolio of trials more than doubled in number to 15, and more trials are expected to commence in the coming year; we have achieved financial stability; and are strengthening our capabilities in translational research.”

A/PROF PHILIP BEALE | CHAIR ANZGOG
BSc, MBBS, FRACP, PhD
GOAL 01
Clinical Research

Undertake a diverse portfolio of clinically important research in gynaecological cancer that has the greatest potential to improve patient outcomes.

“We need to continue to develop better treatments as well as access to preventive measures, so more women in Australia and around the world can live a long and happy life.”

Associate Professor Linda Mileshkin - ANZOG Director
## Clinical Trials

### AUTO-CHECK

**Title:** Molecular determinants of autoimmunity and immune-related adverse events in advanced cancer patients treated with immune checkpoint inhibitors.

**Principal Investigator:**
- A: Matthew Cook
- B: Sonia Yip

**Collaborations:** Initiated in Australia under the Genomic Cancer Clinical Trials Initiative (GCCTI) involving multiple cancer co-operative trials groups: ANZGOG, ALTG, ANZUP and COGNO.

**Contact:** autocheck@ctc.usyd.edu.au

**Funding:** Cancer Australia

**Sites:** Recruiting across 6 studies

### ECHO

**Title:** A Phase III randomised, controlled trial of exercise during chemotherapy for patients commencing first line treatment for ovarian cancer.

**Principal Investigator:** Sandi Hayes

**Collaborations:** Initiated in Australia by ANZGOG

**Contact:** echo@ctc.usyd.edu.au

**Funding:** Cancer Australia; World Cancer Research Fund

**Sites:** Recruiting across 8 sites

### EMBRACE

**Title:** A Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2.

**Principal Investigator:** Katrin Sjoquist

**Collaborations:** Initiated in Australia in collaboration with ANZGOG and Breast Cancer Trials

**Contact:** embrace@ctc.usyd.edu.au

**Funding:** Cancer Australia

**Sites:** Recruiting across 4 sites
RECRUITING CONT.

<table>
<thead>
<tr>
<th>Study</th>
<th>STATEC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title</td>
<td>A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer.</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Alison Brand</td>
</tr>
<tr>
<td>Collaborations</td>
<td>Gynecologic Cancer InterGroup (GCIG) trial led by Cancer Research UK, ANZGOG lead group for Australia and New Zealand.</td>
</tr>
<tr>
<td>Contact:</td>
<td><a href="mailto:statec@ctc.usyd.edu.au">statec@ctc.usyd.edu.au</a></td>
</tr>
<tr>
<td>Funding:</td>
<td>NHMRC Project Grant</td>
</tr>
<tr>
<td>Sites:</td>
<td>Recruiting across 8 sites</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study</th>
<th>feMMe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title</td>
<td>A Phase II randomised clinical trial of Mirena® ± Metformin ± weight loss intervention in patients with early stage cancer of the endometrium</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Andreas Obermair</td>
</tr>
<tr>
<td>Collaborations</td>
<td>Initiated in Australia by the Queensland Centre for Gynaecological Cancer collaboratively with ANZGOG.</td>
</tr>
<tr>
<td>Contact:</td>
<td><a href="mailto:ao@surgicalperformance.com">ao@surgicalperformance.com</a></td>
</tr>
<tr>
<td>Funding:</td>
<td>Lord Mayors Community Trust; UQ Academic Title Holders Grant; Cherish Women’s Cancer Foundation; RBWH Foundation; Cancer Australia; ANZGOG.</td>
</tr>
<tr>
<td>Sites:</td>
<td>Recruiting across 17 sites</td>
</tr>
</tbody>
</table>

IN DEVELOPMENT

<table>
<thead>
<tr>
<th>Study</th>
<th>ICON9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title</td>
<td>An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Linda Mileshkin</td>
</tr>
<tr>
<td>Collaborations</td>
<td>Gynecologic Cancer InterGroup (GCIG) trial led by Cancer Research UK, ANZGOG lead group for Australia and New Zealand.</td>
</tr>
<tr>
<td>Contact:</td>
<td><a href="mailto:icon9@ctc.usyd.edu.au">icon9@ctc.usyd.edu.au</a></td>
</tr>
</tbody>
</table>
### Study SOLACE2
**Title**
A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects.

**Principal Investigator**
Clare Scott & Chee Lee
Magdalena Plebanski (Translational Chair)

**Collaborations**
Initiated in Australia by ANZGOG

**Contact:**
solace2@ctc.usyd.edu.au

**Funding:**
AstraZeneca; ANZGOG OASIS Initiative Grant

**Sites:**
17 sites planned

### Study AtTEND
**Title**
Phase III Double-blind Randomised Placebo Controlled Trial of Atezolizumab in Combination with Paclitaxel and Carboplatin in Women with Advanced/Recurrent Endometrial Cancer.

**Principal Investigator**
Yoland Antill

**Collaborations**
Led by the Mario Negri Gynecologic Oncology group (MaNGO), Italy; ANZGOG lead group for Australia and New Zealand.

**Contact:**
attend@ctc.usyd.edu.au

**Funding:**
MaNGO supported by Roche

**Sites:**
18 sites planned

### Study STICs and STONEs
**Title**
A randomized phase II double-blind placebo-controlled trial of acetylsalicylic acid (ASA) in chemoprevention of ovarian cancer in women with BRCA 1 and 2 mutations.

**Principal Investigator**
Kelly-Anne Phillips

**Collaborations**
Canadian Cancer Trials Group (CCTG), Canada; ANZGOG lead group for Australia and New Zealand.
## Clinical Trials

### IN DEVELOPMENT CONT.

<table>
<thead>
<tr>
<th>Study</th>
<th>MOCCA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title</strong></td>
<td>A multicentre Phase II randomised trial of durvalumab (MEDI4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinomas.</td>
</tr>
<tr>
<td><strong>Principal Investigator</strong></td>
<td>Michael Friedlander</td>
</tr>
<tr>
<td><strong>Collaborations</strong></td>
<td>National University Health System (NUHS) Singapore led international trial, ANZGOG lead group for Australia and New Zealand.</td>
</tr>
<tr>
<td><strong>Contact</strong></td>
<td><a href="mailto:research@anzgog.org.au">research@anzgog.org.au</a></td>
</tr>
<tr>
<td><strong>Funding</strong></td>
<td>NUHS supported by AstraZeneca</td>
</tr>
<tr>
<td><strong>Sites</strong></td>
<td>NUHS supported by AstraZeneca</td>
</tr>
</tbody>
</table>

### CLOSED TO RECRUITMENT

<table>
<thead>
<tr>
<th>Study</th>
<th>REZOLVE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title</strong></td>
<td>A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant ovarian cancer.</td>
</tr>
<tr>
<td><strong>Principal Investigator</strong></td>
<td>Katrin Sjoquist</td>
</tr>
<tr>
<td><strong>Collaborations</strong></td>
<td>Initiated in Australia by ANZGOG</td>
</tr>
<tr>
<td><strong>Contact</strong></td>
<td><a href="mailto:resolve@ctc.usyd.edu.au">resolve@ctc.usyd.edu.au</a></td>
</tr>
<tr>
<td><strong>Funding</strong></td>
<td>Cancer Australia; seed funding from the University of Sydney and Ovarian Cancer Research Foundation.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study</th>
<th>PHAEDRA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Title</strong></td>
<td>A Phase II trial of durvalumab (MEDI4736) in advanced endometrial cancer.</td>
</tr>
<tr>
<td><strong>Principal Investigator</strong></td>
<td>Yoland Antill</td>
</tr>
<tr>
<td><strong>Collaborations</strong></td>
<td>Initiated in Australia by ANZGOG</td>
</tr>
<tr>
<td><strong>Contact</strong></td>
<td><a href="mailto:phaedra@ctc.usyd.edu.au">phaedra@ctc.usyd.edu.au</a></td>
</tr>
<tr>
<td><strong>Funding</strong></td>
<td>AstraZeneca</td>
</tr>
<tr>
<td><strong>Sites</strong></td>
<td>Recruiting across 12 sites</td>
</tr>
<tr>
<td>Study</td>
<td>Title</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Study</td>
<td>Phase II study of intravenous Vinorelbine in patients with relapsed platinum resistant or refractory C5 high grade serous, endometrioid, or undifferentiated primary peritoneum, fallopian tube or ovarian Cancer.</td>
</tr>
<tr>
<td>Study</td>
<td>A Phase II study of durvalumab (MEDI4736) and tremelimumab in combination with neoadjuvant carboplatin and paclitaxel in newly diagnosed women with advanced high grade serous ovarian, fallopian tube and peritoneal cancers.</td>
</tr>
<tr>
<td>Study</td>
<td>A Phase II signal-seeking trial of the clinical benefit rate associated with pamiparib in subjects with germline or somatic BRCA1/2 high grade serous ovarian cancer or carcinosarcoma who have progressed on P-gp substrate chemotherapy or PARP inhibitors with the presence of an ABCB1 fusion and the absence of a BRCA1/2 reversion.</td>
</tr>
</tbody>
</table>
### Centres Participating in ANZGOG Trials

As at 30 June 2018

**QUEENSLAND**
- Gold Coast University Hospital
- Greenslopes Private Hospital
- ICON Cancer Care
- Mater Adult Hospital
- Mater Private Hospital
- Nambour General Hospital
- Old Centre for Gynaecological Cancer Research
- Pindara Private Hospital
- Royal Brisbane and Women’s Hospital
- The Townsville Hospital
- The Wesley Hospital

**NEW SOUTH WALES**
- Calvary Mater Newcastle
- Campbelltown Hospital
- Coffs Harbour Health Campus
- Gosford Hospital
- Newcastle Private Hospital
- Northern Cancer Institute
- Port Macquarie Base Hospital
- Prince of Wales Hospital
- Riverina Cancer Centre
- Royal Hospital for Women
- Royal Prince Alfred Hospital
- Chris O’Brien Lifehouse

**KEY**
- Site currently open to recruitment
- Site selected but not yet open

<table>
<thead>
<tr>
<th>ECHO</th>
<th>PHARMA</th>
<th>SATEC</th>
<th>ICON9</th>
<th>VIP</th>
<th>IPRIME</th>
<th>EMBRACE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Location</td>
<td>Hospitals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **NEW SOUTH WALES** | Royal North Shore Hospital  
St George Hospital  
Westmead Hospital  
Canberra Hospital  
Border Medical Oncology  
Monash Medical Centre - Clayton  
Monash Medical Centre - Moorabbin  
Mercy Hospital for Women  
Peter MacCallum Cancer Centre  
The Royal Women's Hospital  
Cabrini Hospital |
| **ACT**           | Royal Hobart Hospital  
Flinders Medical Centre  
Royal Adelaide Hospital  
King Edward Memorial Hospital  
Sir Charles Gairdner Hospital  
St John of God Hospital, Subiaco  
St John of God Hospital, Murdoch  
Fiona Stanley Hospital  
Hollywood Private Hospital  
Linear Clinical Research  
Auckland Hospital  
Christchurch Hospital  
Wellington Hospital |
Publications

2018 Abstracts

2018 Manuscripts


2017 Abstracts

2017 Manuscript

The Fund for New Research Grants support pilot and pre-clinical studies that are identified as providing data that may lead to a clinical trial and also supports innovative sub-studies and young or new investigator’s studies. Each year a maximum of three grants up to $50,000 are offered. Two studies were funded in the 2017-2018 year.

<table>
<thead>
<tr>
<th>Study</th>
<th>PHAEDRA Translational Sub-study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title</td>
<td>Molecular and Genomic correlations with clinical response to Durvalumab in Advanced Endometrial Cancer</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Amanda Spurdle</td>
</tr>
<tr>
<td>Collaborations</td>
<td>ANZGOG collaboration with QIMR Berghofer Medical Research Institute</td>
</tr>
<tr>
<td>Contact:</td>
<td><a href="mailto:Amanda.spurdle@qimrberghofer.edu.au">Amanda.spurdle@qimrberghofer.edu.au</a></td>
</tr>
<tr>
<td>Sites:</td>
<td>N/A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study</th>
<th>EMBRACE Translational Sub-study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title</td>
<td>Understanding resistance and sensitivity to PARP inhibitors in Homologous Recombination deficient (HRD) high grade serous ovarian cancer; translational research from the EMBRACE clinical trial.</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Katrin Sjoquist</td>
</tr>
<tr>
<td>Collaborations</td>
<td>ANZGOG collaboration with NHMRC Clinical Trials Centre, University of Sydney</td>
</tr>
<tr>
<td>Contact:</td>
<td><a href="mailto:Katrin.Sjoquist@ctc.usyd.edu.au">Katrin.Sjoquist@ctc.usyd.edu.au</a></td>
</tr>
<tr>
<td>Sites:</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Also supported by ANZGOG in 2017-2018:

<table>
<thead>
<tr>
<th>Study</th>
<th>WHAM (What happens after menopause?) A multi centre prospective study.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title</td>
<td>Impact of risk reducing bilateral salpingo-oophorectomy on non-cancer outcomes in young high risk women.</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Martha Hickey</td>
</tr>
<tr>
<td>Collaborations</td>
<td>ANZGOG collaboration with The Royal Women’s Hospital, Melbourne</td>
</tr>
<tr>
<td>Contact:</td>
<td><a href="mailto:hickeym@unimelb.edu.au">hickeym@unimelb.edu.au</a></td>
</tr>
<tr>
<td>Funding:</td>
<td>ANZGOG grant</td>
</tr>
</tbody>
</table>
GOAL 02

Translational Research

Build capacity for translational research in gynaecological cancer through the development of a national gynaecological cancer biobank.

“TR-ANZGOG will add a whole new dimension to gynae-cancer clinical trials in Australasia. It has the potential to benefit not only Australian women, but women around the world diagnosed with gynaecological cancers. Clinical trials tell us whether a particular drug or intervention improves survival. TR-ANZGOG helps us to investigate WHY the drug tested in the trial works, or doesn’t work, at an individual patient level.”

Professor Anna de Fazio, Chair,
TR-ANZGOG Steering Committee
TR-ANZGOG

TR-ANZGOG is an ANZGOG research initiative established to achieve a strategic goal to build capacity for translational research by supporting the collection of biospecimens associated with all ANZGOG trials. Additionally, it aims to provide enduring custodianship and maximize the use of biospecimens through research.

2018 marked the next phase of TR-ANZGOG implementation following funding success and commencement of a Project Manager, Claire Davies. Claire is a medical scientist, specialising in Anatomical Pathology. With over fifteen years’ career experience in diagnostic and clinical research environments (primarily gynaecological oncology), both locally and internationally, Claire brings to TR-ANZGOG broad expertise and knowledge in translational research processes.

A TR-ANZGOG steering committee has been established, Chaired by Prof Anna de Fazio. The committee is comprised of a diverse panel of experts whose specialties include pathology, clinical trial management, pure science research, surgery, oncology, ethics and operations. Members include A/Prof Philip Beale, A/Prof Lyndal Anderson, Prof Clare Scott, A/Prof Pamela Pollock, Prof David Bowtell, A/Prof Alison Brand, Dr Alison Davis, Dr Michelle Vaughan and A/Prof Linda Mileshkin.

Preliminary work has focussed on strategy planning, connecting with key people and securing further funding for TR-ANZGOG.

ANZGOG would like to thank the Rose Varga Bequest and the John T Reid Charitable Trusts for their support, in recognition of the importance of the TR-ANZGOG initiative.

TR-ANZGOG is an exciting opportunity in our aim to improve outcomes for women with gynaecological cancer by stimulating new translational research projects and clinical trials, and by promoting collaboration.

FIGURE 1: TR-ANZGOG CONCEPT

- A mechanism for ANZGOG trial investigators to apply for access to TR-ANZGOG to manage biospecimen collection and processing and facilitate translational aspects of the trial.
- On-line Information and Resource portal including application forms, SOPs, document templates, collaborator details, publications and an inventory of clinically annotated specimens.
- A national network of lab-based facilities to aid in collection and processing of specimens on behalf of ANZGOG trials.
- A designated biobank/laboratory for long-term custodianship and dissemination of clinical-trial related biospecimens to facilitate future translational research.
- A mechanism to apply to TR-ANZGOG for use of biospecimen and data for research.
- Feed back of research results to TR-ANZGOG from translational studies to build knowledge base.
GOAL 03
Collaboration

Build capacity for gynaecological cancer research in Australia through collaboration with relevant national and international groups with a focus on Asia.

ANZGOG’s international collaborations are fostered through its membership of the Gynecologic Cancer InterGroup with 28 member countries. Our focus on Asia has brought two trials to Australia and more are in development. Collaborations with institutions such as Sydney and Melbourne Universities, Walter Eliza Hall Medical Research Institute, QIMR Berghofer, Queensland University of Technology and University of Western Australia are ensuring a diverse approach to research ideas and clinical trial development.
The 2018 ANZGOG Annual Scientific Meeting (ASM) took place in Brisbane from 4 to 7 April, with the theme “Challenges in Precision Gynaecological Cancer in a Molecular Era”. A total of 235 members of ANZGOG attended the ASM.

The ANZGOG ASM gives researchers, clinicians, nurses and clinical research officers the opportunity to hear about the research being generated by ANZGOG and its international collaborators. It is also an opportunity to build collaborations with overseas guests and their research units, and learn about new approaches to gynaecological cancer treatment.

The 2018 ASM theme focused on the many challenges in this new era of targeted therapy, including:

- Improving efficacy of novel targeted therapies by using combinations of drugs
- Availability, timing and access to tumour testing
- Cost and access to targeted therapies
- Identifying those patients likely to respond to novel agents
- How to appropriately measure the impact of treatments on quality of life

INTERNATIONAL GUEST SPEAKERS

Three world-leading clinical researchers spoke at the ASM.

Dr Martee Hensley from Memorial Sloan Kettering Cancer Center in New York, USA gave the first plenary presentation on the challenges of caring for women with uterine sarcomas – a rare group of diseases, many with a very poor prognosis, even when diagnosed at an early stage. Dr Hensley spoke of the opportunity to explore how molecular testing may improve diagnostic classification and precision, whether molecular profiling may yield prognostic information, and whether such testing can identify potential treatment targets for a subset of patients. Her talk highlighted the challenges of treating women with these rare gynaecological malignancies.

Professor Michael Milosevic, Radiation Oncologist from Princess Margaret Cancer Centre, Toronto, Canada spoke about cervical cancer, which remains a global health problem. Few, if any, drugs have been identified previously that, when combined with curative radiotherapy, both improve treatment response and reduce side effects. Professor Milosevic spoke about an exciting novel drug that in pre-clinical models of cervical cancer does precisely that, and it is hoped that this agent will soon enter clinical trials.

Associate Professor Jessica McAlpine, a Gynaecological Oncologist from the British Columbia Cancer Agency in Vancouver, Canada spoke about endometrial cancer – the most common gynecologic cancer in the developed world, increasing in both incidence and mortality. Associate Professor McAlpine’s talk reviewed the need for, evolution of, and applications (tested and intended) for novel molecular classifiers in endometrial cancer.

Highlight presentations from local presenters included sessions on Immunotherapy, Quality of Life and Survivorship, Translational ANZGOG and Pathology, and a presentation about ANZGOG’s Survivors Teaching Students awareness program.
AWARDS PRESENTATIONS

General Oral Abstract: a tie between Associate Professor Penny Webb, and Professor Michael Friedlander who presented “The hidden burden of anxiety and depression in ovarian cancer: a prospective longitudinal study from diagnosis”; and “Getting the most out of follow-up: a prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT)”

Poster award: Dr Rachel Delahunty, “TRACEBACK: Finding BRCA1 and BRCA2 mutations in women with ovarian cancer diagnosed prior to changes to genetic testing guidelines”

Pure Science Oral Abstract Award: Dr Gwo-Yaw Ho, “Eribulin as a novel treatment candidate for ovarian and fallopian tube derived carcinosarcoma”

Pure Science Poster Award: a tie between Dr Emily Colvin, “Expression of lncRNAs in ovarian cancer-associated fibroblasts is prognostic for patient survival”; and Luqman Jubair whose work was presented by PhD supervisor Professor Nigel McMillan, “Gene editing using CRISPR/CASIS highly effective for HPV-driven cancers”

PUBLIC FORUM: CHALLENGING THE STATUS-QUO OF WOMEN’S CANCERS

A Public Forum was held immediately following the ASM on the Saturday afternoon to provide insights into ANZGOG’s research and cancer treatments for women with a gynaecological cancer, their families and friends. The Forum attracted 45 attendees from Brisbane, Melbourne, Adelaide and Perth, with an additional 333 viewing online from major cities and regional towns across Australia.

Presentations on recent developments and new trials in the three main tumour types were delivered by Associate Professor Alison Brand (endometrial), Dr Paul Cohen (cervical), and Professor Clare Scott (ovarian). Two presentations were given from ovarian cancer survivors and volunteers with the Survivors Teaching Students (STS) program, Jane Power and Kristen Larsen. Dr Helen Gooden presented on STS and Julijana Trifunovic promoted opportunities to raise funds for ANZGOG’s research through our major fundraising campaigns.
Thank you to our Sponsors

Platinum Sponsor & Pure Science Session Sponsor

Gold Sponsor

Workshop Sponsor

Session Sponsor

Exhibitors

Exhibitors

Exhibitors

Best of the Best Awards

Best of the Best Awards
GOAL 04

Leadership

Be recognised as the leader in gynaecological cancer research in Australia and New Zealand, by clinicians, consumers and cancer organisations.

Engaging with women, their families and friends to raise awareness about gynaecological cancer research has fostered an amazing army of supporters for ANZGOG’s work. Along with leadership through our Annual Scientific Meeting, ANZGOG now conducts education for trainees, forums for the public and education for doctors and nurses through Survivors Teaching Students.
Survivors Teaching Students® (STS) is a volunteer program that brings the faces and voices of ovarian cancer survivors and caregivers into the classrooms of health professional students to teach them about women’s experiences with the disease. ANZGOG is leading the program here in Australia.

We have now completed our first full year of STS having started in 2017 after being awarded a Cancer Australia Supporting people with cancer Grant, funded by the Australian Government, to establish the program over the three year period 2017 – 2020, with a requirement that the program continues beyond this initial period.

Due to the high demand from schools and interest from women and caregivers affected by ovarian cancer, we are outperforming our specified goals in the first year of operation.

Key Achievements (FY 2017-18):

Enrolled 6 university programs in two states - NSW and Victoria

Recruited and trained/training 60 volunteers from across Australia.

Delivered 9 presentations, reaching 300 students medical and nursing students

Pre and post-evaluations showed effectiveness percentages for medical schools of 23% and 32% for nursing (under and postgraduate) compare favourably with the US Program

Presented Survivors Teaching Students at 4 national conferences

Due to the nature of the disease, we are always recruiting new volunteers and welcome enquiries to take part in the program. Our pool of volunteers is always changing due to the demands of the disease, advancing illness and at times, death.

ANZGOG is committed to our duty of care to our STS volunteers. We value the support of two psycho-oncologists, Cath Adams and Toni Lindsay, who work with us in STS to ensure our survivors work safely in the STS program.
Save the Box Launch

On Thursday 30 August 2018, ANZGOG launched the inaugural ‘Save the Box’ brunch at the Nobel Trust Suite at the Sydney Cricket Ground, with Women in Sport, to recognise International Gynaecological Cancer Awareness Month.

The Save the Box Launch “More Precious than Gold” brunch brought together women in sport and women living with a gynaecological cancer, or those affected by it. We began the conversation with a beautiful brunch and a robust panel discussion on the eve of International Gynaecological Cancer Awareness Month. The panel talked about the importance of women and sport, and the importance of raising awareness and talking openly with your peers, family and work colleagues about women’s health issues.

Gretel Killeen, who was fabulous as the guest host, introduced our special guest panel:

The Hon. Stuart Ayres MP – NSW Minister for Sport

Heather Hawkins – Ovarian Cancer survivor and Ultramarathon champion

Associate Professor Philip Beale – Chair of ANZGOG

Alicia Quirk OAM – Australian Rugby Union Player, Olympics Gold Medalist

Katrina Cochrane – Network Leader, Australian Fitness Network

Sarah Hill - CEO Greater Sydney Commission, National Rower, Director NSW Rowing

Special thank you to Gretel and all of the panel members for kindly donating their time for our event.
Community Support

Save the Box Community Activities in Focus

**Sally Catt** inspiringly swam against huge tides to cross the English Channel and raised $7,550 for Save the Box. The swim took 14 hours and 8 minutes - setting off in the dark at 11pm from the English coast. Sally swam in recognition and support of her friend Caitlin Delaney who was diagnosed with stage 4 ovarian cancer in January 2017.

**Alisha Thompson** - has raised just under $22,500 for Save the Box and has since increased her target to a lifetime goal of $100,000! Alisha has stage 4 ovarian cancer and is focused on raising funds for gynaecological cancer research and in equal importance, raising awareness of gynaecological cancer symptoms and the importance of research into these cancers.

**Fiona Price** and her seven friends decided on a dramatic approach to fundraising and settled on jumping out of a plane at 11,000 feet! The eight women put on their Save the Box t-shirts and leapt out over the blue skies of Tasmania, raising $9,000!
WOMEN’S CANCER FOUNDATION

We Can Walk it Out 2018

We Can Walk it Out 2018, now in its 16th year, was a great event for the Women’s Cancer Foundation. With over 500 adults, children and dogs in attendance, the weather was perfect. Key Ambassadors attended the event showing their commitment and support for women with a gynaecological cancer. Denise Scott was once again fabulous as the MC, with Jana Pittman helping with the warm up and speaking about cervical cancer and Charlie Brown (Ambassador at Large) acknowledging and thanking all of the participants on behalf of ANZGOG.

Team Teal 2018

This year Team Teal, where the Harness Racing fraternity supports Women’s Cancer Foundation, went one step further by going international! Harness Racing New Zealand has now also taken up the reins to support ovarian cancer research. Throughout Australia and New Zealand, reinswomen wear teal pants on the track and race against each other and men, to try and cross the finish line first, where $200 is donated by the club and then matched by the wagering group. Other fundraising activities also take place around the track, such as teal cupcakes, merchandise selling and raffles.

The activity that runs over a six week period, through February to mid-March, is now a significant event in the Harness Racing Industry thanks to Duncan McPherson OAM and Michael Taranto, Chairman of Harness Racing Australia. They have agreed on a three year partnership and hope to increase our fundraising targets significantly in the future. This year the event raised over $155,000.
Community Support

Night at the Trots

What a fabulous night! In total, over $92,000 was raised. Held annually at TABCORP Park in Melton Victoria and hosted by Harness Racing Victoria, this year’s event attracted 350 people in attendance. The Lyn McPherson Memorial Race is the signature race, where everyone remembers those we have lost to ovarian cancer.

Special thanks to Patron and founder Duncan McPherson OAM and Michael Taranto, Chairman of Harness Racing Australia, for their support. Also thank you to the sponsors, prize donors and everyone who attended.

Marathon for Women’s Cancer Foundation

Thomas (Tom) and Duncan McPherson OAM, long-time supporters of Women’s Cancer Foundation, have upped the ante with their fundraising for research into ovarian and gynaecological cancer. Their fundraising began when Tom’s mother (Duncan’s wife) Lyn, passed away in 2010 from ovarian cancer. This year together (a first for Duncan) they took part in the Iron Man competition, taking on the half marathon in Busselton (WA) and raised over $21,500! We would like to thank the McPherson family for their continued commitment to the Women’s Cancer Foundation and ANZGOG.

GO For Gynae and other ANZGOG Fundraising Activities

GO Step for Gynae

The month of May acknowledges fitness, ovarian cancer and cancer research so we felt what better month to do GO Step for Gynae in 2018. There has been a large increase in women being diagnosed with endometrial cancer and one contributing factor is the obesity epidemic. Over $22,000 was raised, with Jill Emberson raising the most at $8,000. Thank you to everyone who participated.

Women in Drinks – The Drinks Association

In 2018 Women in Drinks throughout Australia once again came together and raised over $15,000 at their International Women’s Day event at Luna Park in Sydney, and also fundraised throughout the year at their state networking events. We are extremely grateful for their ongoing support of ANZGOG’s work.
GOAL 05
Financial Sustainability

Become a financially sustainable organisation, not reliant on grant funding for core business by 2018.

“ANZGOG is in a very strong financial position. Our balance sheet is very good with total equity of $5,229,685 and programs are in place to continue growth and funding for research.”

Mr David Rogers, Non-Executive Finance Director, ANZGOG Board
# Measuring Our Performance

- **SG1 – A diverse portfolio of clinically important research in gynaecological cancers**
  - Grow diversity of research portfolio to include earlier phase clinical trials
  - Number of ovarian cancer trials underway:
    - 2016: 3
    - 2017: 2
    - 2018: 8
  - Number of endometrial cancer trials underway:
    - 2016: 2
    - 2017: 3
    - 2018: 3
  - Number of cervical cancer trials underway:
    - 2016: 1
    - 2017: 1
    - 2018: 2
  - Number of Quality of Life studies underway:
    - 2016: 3
    - 2017: 1
    - 2018: 0
  - Other types of trials including rare tumour studies underway:
    - 2016: 1
    - 2017: 1
    - 2018: 0
  - Foster new research ideas and support via collaborations and funding
    - Fund for New Research Grants awarded:
      - 2016: 3
      - 2017: 2
      - 2018: 2
    - OASIS Initiative Grants awarded:
      - 2016: 1
      - 2017: 3
      - 2018: 0
    - Collaborative studies supported by ANZGOG:
      - 2016: 2
      - 2017: 8
      - 2018: 12
  - In partnership with government and collaborators we continue to increase the opportunities for women to participate in gynaecological cancer clinical trials
    - Increase the number of gynaecological cancer clinical trials conducted annually:
      - 2016: 9
      - 2017: 8
      - 2018: 13
    - Increase the number of clinical sites actively participating in gynaecological cancer clinical trials (including international sites conducting ANZGOG collaborative studies)**:
      - 2016: 529
      - 2017: 433
      - 2018: 49
    - Increase participation in clinical trials by women affected with gynaecological cancer ** (2017 - two major trials closed to recruitment, OUTBACK and Symptom Benefit):
      - 2016: 761
      - 2017: 1004
      - 2018: 105
  - Translating research into practice
    - Number of publications of research results:
      - 2016: 11
      - 2017: 23
      - 2018: 7
    - Trials changing clinical practice:
      - ICON7
      - Portec 3
  - Develop independent cancer clinical trials to the stage of applying for grant and other funding (in collaboration with the NHMRC Clinical Trials Centre)
    - Government grants awarded for research and research support:
      - 2016: $1,335,701
      - 2017: $964,954
      - 2018: $1,299,086
    - Other funding provided for research and research support:
      - 2016: $489,121
      - 2017: $583,035
      - 2018: $622,801
  - Clinical trials design and protocol development
    - Number of new concepts or studies presented to ANZGOG:
      - 2016: 25
      - 2017: 26
      - 2018: 22
    - Number of new concepts in development with ANZGOG:
      - 2016: 6
      - 2017: 6
      - 2018: 14
  - Increase the professional capacity to conduct clinical trials in Australia through member growth, education and training in clinical trials design
    - Number of people attending Annual Scientific Meetings:
      - 2016: 262
      - 2017: 231
      - 2018: 235
    - Increase in clinical professionals joining as members:
      - 2016: 703
      - 2017: 770
      - 2018: 857
## Measuring Our Performance

### Actions and Measurables

<table>
<thead>
<tr>
<th>Description</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SG2 - Set up a national gynaecological cancer biobank</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Build capacity for translational research in gynaecological cancer through the development of a national gynaecological cancer biobank</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Establish a working group to explore the options and identify steps to achieve</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Draft strategy in consultation TR-ANZGOG Strategy Approved TR-ANZGOG Project Manager appointed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SG3 – Build gynaecological cancer research capacity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Build collaboration with national organisations</td>
<td>3</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Number of collaborations with other cancer clinical trials groups</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Build collaboration with international groups working in the gynaecological cancer research</td>
<td>428</td>
<td>336</td>
<td>0</td>
</tr>
<tr>
<td>- Increase in international sites conducting ANZGOG trials **</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Number of collaborations with international gynaecological cancer groups **</td>
<td>4</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>International keynote speakers at Annual Scientific Meetings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- International keynote speakers at Annual Scientific Meetings</td>
<td>4</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td><strong>SG4 – recognised as the leader in gynaecological cancer research</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Communicate the breadth of ANZGOG’s research focus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Twice annual ResearchHER for consumers and the general public</td>
<td>Achieved</td>
<td>Achieved</td>
<td>Achieved</td>
</tr>
<tr>
<td>- Twice annual TRIALS - in-depth news on gynaecological cancer trials for members and cancer professionals</td>
<td>Achieved</td>
<td>Achieved</td>
<td>Once</td>
</tr>
<tr>
<td>We support new research ideas with funding to get started.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- New Research Grants awarded</td>
<td>3</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td><strong>Raising awareness of clinical trials amongst consumers</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of participants in consumer information sessions in person and through webinars</td>
<td>65</td>
<td>389</td>
<td>378</td>
</tr>
<tr>
<td>Number of likes on Facebook (established 21 July 2014)</td>
<td>4,593</td>
<td>7,532</td>
<td>14,504</td>
</tr>
<tr>
<td><strong>Raising awareness of clinical trials amongst the public</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of general public reached via information events</td>
<td>2000+</td>
<td>2,319</td>
<td>1,527</td>
</tr>
</tbody>
</table>
## Measuring Our Performance

### Actions and Measurables

<table>
<thead>
<tr>
<th>Growing capacity of consumers supporters</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conduct two education and training programs for our consumer advisory panel annually</td>
<td>Achieved</td>
<td>Achieved</td>
<td>Achieved</td>
</tr>
<tr>
<td>Number of Volunteer Ambassadors supporting ANZGOG</td>
<td>9</td>
<td>17</td>
<td>147</td>
</tr>
</tbody>
</table>

**SGS**

### Growing support from non-government sectors for gynaecological cancer research

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase donations, bequests, community support</td>
<td>$812,269</td>
<td>$806,179</td>
<td>$2,430,048</td>
</tr>
<tr>
<td>Gain on acquisition of Womens’ Cancer Foundation</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Increase corporate sponsorship</td>
<td>$123,866</td>
<td>$208,927</td>
<td>$193,191</td>
</tr>
<tr>
<td>Number of bequests per annum</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

### Supporting Infrastructure costs with grants

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage of infrastructure costs supported by grants</td>
<td>81.2%</td>
<td>89.3%</td>
<td>71.1%</td>
</tr>
</tbody>
</table>

### Growing and maintaining our investments to cover 12 months of operational expenditure, to secure us against future funding shortfalls.

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Months of operational expenditure covered by cash reserves</td>
<td>20.2</td>
<td>26.6</td>
<td>27.3</td>
</tr>
<tr>
<td>Investment return per annum</td>
<td>1.4%</td>
<td>1.3%</td>
<td>1.6%</td>
</tr>
</tbody>
</table>

### Our people

In collaboration with the NHMRC Clinical Trials Centre (CTC) we have an engaged and skilled paid workforce.

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANZGOG staff, headcount excluding casuals (and as FTE)</td>
<td>8 (5.6 FTE)</td>
<td>9 (6.4 FTE)</td>
<td>13 (8.6 FTE)</td>
</tr>
<tr>
<td>CTC staff working on ANZGOG trials, headcount</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
</tbody>
</table>
ASSOCIATE PROFESSOR PHILIP BIALE
Associate Professor Beale is Director of Cancer Services and Director of Palliative Care, Sydney Local Health District, Head of Medical Oncology Department at Concord Hospital, Senior Staff Specialist at RPA, and at Chris O'Brien Lifehouse and Associate Professor at the University of Sydney. He has a special interest in ovarian, breast, colorectal and upper gastrointestinal cancers and is involved in Phase I, II and III clinical trials for all of these cancers and is the PI in several breast and ovarian cancer trials. He has published more than 100 peer reviewed papers. He is the Chair of ANZGOG and is a member of the AGITG and ANZBCTG trials groups.

ASSOCIATE PROFESSOR ALISON BRAND
Alison Brand is a gynaecological oncology surgeon, Director of Gynaecological Oncology at Westmead Hospital, Sydney, NSW and Clinical Associate Professor at the University of Sydney and has been involved in ANZGOG since it was established in 2000 and has since held key positions within the group. She was Chair of the group from 2012 to 2018. She is the Australian PI for the STATEC endometrial cancer surgical trial. She has chaired or been a member of several working parties for the development of national gynaecological cancer guidelines. She was Senior Editor for the International Journal of Gynaecological Cancer. She is passionate about participation in clinical trials as a way to improve the lives of women with gynaecological cancers, now and in the future.

MS SUE BREW
Sue Brew has been a member of the ANZGOG Study Coordinators’ committee since its inception in 2005 and accepted the position as committee chair in 2011. She has been a Study Coordinator in the Department of Medical Oncology, Calvary Mater Newcastle since 1996 and also recently served as member of Hunter New England Human Research Ethics Committee for a period of 8 years 2006 – 2014.

DR ALISON DAVIS
Alison Davis is a Senior Staff Specialist in Medical Oncology at The Canberra Hospital and Conjoint Senior lecturer at the Australian National University. Her subspeciality areas include gynaecological and breast cancer and she is actively involved in clinical research in both areas. Her other interest areas include Cancer Genetics and end of life care. Alison has been involved with ANZGOG for many years and was Deputy Chair of the ANZGOG RAC for two years before becoming Chair in late 2017. She has also been a member of the ANZGOG Audit, ASM and New Research Fund Committees, as well as a member of other regional and national organisations including Advisory Committee Pharmaceutical Medicines 2008-2015, ACT SE NSW Breast Cancer Treatment Group, and Australian Breast Cancer Tissue Bank.

DR JEFFREY GOH
Jeff Goh is a Senior Staff Medical Oncologist (part-time) at Royal Brisbane & Women’s Hospital (RBWH) and a Visiting Medical Oncologist at Greenslopes Private Hospital and ICON Chermside. He is also involved with the University of Queensland as a Senior Lecturer with the Faculty of Medicine. Jeff has been actively involved in clinical trials including his role as Principal Investigator in a number of Phase I, II and III Gynaecological and Urological malignancy trials at Royal Brisbane & Women’s Hospital and Greenslopes Private Hospital. He is currently a co-investigator for several colorectal and pulmonary malignancy trials. Jeff is currently also a board member of ANZGOG and chairs the Cervical Tumour Type Working Group. His particular interests are in gynaecological, urological and colorectal malignancies.

DR PEARLY KHAW
Dr Pearly Khaw is a Radiation Oncologist at the Peter MacCallum Cancer Centre. She is also a clinical researcher and is leading the Radiation Oncology Quality Assurance Program of the PORTEC-3 trial in Australia through the Trans-Tasman Radiation Oncology Group (TROG). Dr Khaw has been a reviewer for the International Journal of Gynecological Cancer, Journal of Medical Imaging and Radiation Oncology, and Practical Radiation Oncology. She was involved in the formation of the Special Interest Group for Radiation Oncologists practicing in the area of Gynae-Oncology through the Royal Australian and New Zealand College of Radiologists. Pearly is a Primary Investigator on the ANZGOG endometrial trial STATEC.
ASSOCIATE PROFESSOR LINDA MILESHKIN
Linda Mileshkin is a clinical researcher who has achieved productive research output whilst maintaining a significant and busy clinical role as a consultant medical oncologist, with a particular interest in the treatment of gynaecological and lung cancers, as well as the supportive care of people affected by cancer. She runs the only specialist Carcinoma of Unknown Primary clinic at the Peter MacCallum Cancer Centre. She is currently involved in multiple clinical research projects involving people with gynaecological and lung cancers, carcinoma of unknown primary (CUP), as well as Phase I trials in multiple tumour types. Linda is currently the international study chair for Outback, an international Australia-led NHMRC funded Phase III trial in cervical cancer.

PROFESSOR CLARE SCOTT
Clare Scott is a Medical Oncologist at the Royal Melbourne Hospital and Royal Women's Hospital and Laboratory Head at the Walter and Eliza Hall Institute of Medical Research, studying drug resistance in ovarian cancer. She has 15 years' experience in clinical cancer genetics, including working in Familial Cancer Clinics and in treating breast and ovarian cancer. In the lab, she focuses on ovarian biology, including the role of apoptosis in infertility and on developing targeted therapies for ovarian cancer in novel ovarian cancer models. She has been awarded a Clinical Fellowship from the Victorian Cancer Agency (2011) and the Sir Edward Dunlop Cancer Research Fellow from the Cancer Council Victoria (2012). Clare is co-chair of the SOLACE2 trial.

ASSOCIATE PROFESSOR PETER SYKES
Peter Sykes is a gynaecological oncologist and Head of Department in Obstetrics and Gynaecology, Christchurch School of Medicine, University of Otago, Christchurch, New Zealand. He completed his initial training in Bristol, UK and has worked in both Australia and New Zealand. His interest area of clinical research in the epidemiology and management of gynaecological cancer has involved a steady record of publication in clinical gynaecological oncology. He has actively recruited and treated patients in international multicentre and single centre research. He is on the ANZGOG Research Advisory Committee and was Program Chair of the 2014 ANZGOG ASGO Combined Scientific Meeting and was Program Chair of the 2015 ANZGOG Annual Scientific Meeting.

MR DAVID ROGERS
David Rogers was with accounting, tax and consulting professional services firm KPMG for 37 years; including 27 years as a partner in the Australian firm. His career has included audit partner and lead partner for many significant companies in a wide range of sectors. In addition, David was a member of the firm's National Board of directors for six years from 2005 to 2011, including two years as Chairman of the firm's Audit Committee, and was prior to his retirement leader of the firm's global audit transformation project.

David is currently a Director and Deputy Chair of the Royal Motor Yacht Club Broken Bay, a member of the Western Sydney Local Health District’s Finance, Performance and Assets Committee and an independent consultant to clients involved in disputes concerning accounting and financial audit matters.

MS RACHAEL SUTTON
Rachael is a Partner in the Holman Webb Workplace Relations group and has 19 years’ experience in employment and workplace law. Rachael is experienced in all aspects of workplace laws and has a strong background in advising public and private sector employers. Rachael was admitted to practice law in October 1997 and has been a partner at Holman Webb since January 2012. She also specialises in food safety and labelling laws and has acted as a prosecutor for the NSW Food Authority for some 14 years. She now advises food businesses, including start-ups in this area. Rachael has presented to many Boards of Directors and senior management teams on employment and work health and safety laws, what due diligence means and how best to comply. Rachael is a member of the NSW Law Society and Industrial Relations Society of NSW.
## Our Committees

### RESEARCH ADVISORY COMMITTEE
- Alison Davis (Chair)
- Michelle Vaughan (Deputy Chair)
- Lyndal Anderson
- Cheryl Waller
- Rhonda Beach
- Candace Carter
- Martin Stockler
- Monica Tang
- Val Gebski
- Sonia Yip
- Alison Brand
- Sam Saidi
- Philip Beale
- Michael Friedlander AM
- Clare Scott
- Peter Sylves
- Michelle Wilson
- Wanda Lawson
- Sandi Hayes
- Pamela Pollock
- Ganessan Kichenadasse
- David Bowtell
- Peter Grant
- Anne Hamilton
- Linda Mileshkin
- Pearly Khaw
- Tarek Meniawy
- Joanne Youd

### OVARIAN TUMOUR GROUP
- Philip Beale (Chair)
- Tarek Meniawy (Deputy Chair from April 2018)
- Rhonda Beach
- Anthony Richards
- Janine Lombard
- Michael Friedlander AM
- Monica Tang
- Rachel O’Connell
- Anna de Fazio
- Bryony Simcock
- Kathryn Chrysal
- Michelle Wilson
- Alison Hadley
- Catherine Shannon
- Jermaine Coward
- David Bowtell
- Clare Scott
- Sumitra Ananda

### STUDY COORDINATORS COMMITTEE
- Sue Brew (Chair)
- David Cannan
- Donna Long
- Kathryn Jenkins
- Belinda Egan
- Elizabeth Wardrop
- Jenny Campbell
- Meghan Leigh
- Vanessa Taylor
- Melissa Groom
- Joanne Youd

### AUDIT RISK COMMITTEE
- David Rogers
- Philip Beale
- Rachael Sutton

### NOMINATIONS COMMITTEE
- Philip Beale
- Alison Brand
- Michael Friedlander AM
- Carol Johnson
- Danny Rishcin

### ANZGOG CTC OPERATIONS EXECUTIVE COMMITTEE
- Philip Beale
- Alison Brand
- Alain Davis
- Martin Stockler
- Candace Carter
- John Andrews
- Peey Siy Kok
- Elisa Carolus
- Alison Evans

### CERVIX TUMOUR GROUP
- Jeffrey Goh (Chair)
- Michelle Harrison (Deputy Chair from April 2018)
- Sam Saidi
- Felicia Roncolato
- Karen Lim
- Kristy Robledo
- Sonia Yip
- Wanda Lawson
- Vivek Arora
- Anne Hamilton
- Kalash Narayan
- Ming Yin Lin

### CONSUMER AND COMMUNITY COMMITTEE
- Helen O’Neill (Chair to April 2018 – 10 years service)
- Penny Stoyles (CCC member to April 2018 – 10 years service)
- Wanda Lawson (Chair of Consumer Research Panel from April 2018)
- Cheryl Walker
- Rhonda Beach
- Lisa Finucane
- Leonie McQuire
- Fiona Price
- Kathryn Comerwaile

### QUALITY ASSURANCE COMMITTEE
- Pearly Khaw (Chair)
- Alison Brand
- Michelle Harrison
- Belinda Egan
- Alison Hadley
- Philip Chan
- Maheesh Iddawela
- Ganendra Raj Kader Ali Mohan

### ANZGOG RESEARCH MANAGEMENT GROUP
- Michael Friedlander AM (Chair)
- Sue Brew
- Philip Beale
- Alison Brand
- Bo Gao
- Chee Khiong Lee
- Anna de Fazio
- Michelle Wilson
- Karen Livingstone
- David Bowtell
- Clare Scott
- Linda Mileshkin
- George Au-Yeung
- Tarek Meniawy

### OVASIS STEERING COMMITTEE
- Michael Friedlander AM (Chair)
- Sue Brew
- Philip Beale
- Alison Brand
- Pearly Khaw
- Rachel Delahunty

### UTERINE TUMOUR GROUP
- Diana Adams (Chair until February)
- Yoland Antill (Chair from April 2018)
- Rhonda Farrell (Co-Chair from April 2018)
- Elizabeth Barnes
- Cheryl Waller
- Peey Siy Kok
- Sinivas Kondalakramy-Chananesan
- Andrea Garrett
- Amanda Spurle
- Eva Baxter
- Pamela Pollock
- Ganessan Kichenadasse
- Mahesh Iddawela
- Pearly Khaw
- Rachel Delahunty

### STUDY COORDINATORS COMMITTEE
- Sue Brew (Chair)
- David Cannan
- Donna Long
- Kathryn Jenkins
- Belinda Egan
- Elizabeth Wardrop
- Jenny Campbell
- Meghan Leigh
- Vanessa Taylor
- Melissa Groom
- Joanne Youd

### ANZGOG RESEARCH MANAGEMENT GROUP
- Philip Beale
- Alison Brand
- Alain Davis
- Michelle Vaughan
- Alison Evans
- Tracey Meares

### STAFF AUDIT RISK COMMITTEE
- David Rogers
- Philip Beale
- Rachael Sutton

### NOMINATIONS COMMITTEE
- Philip Beale
- Alison Brand
- Michael Friedlander AM
- Carol Johnson
- Danny Rishcin

### ANZGOG CTC OPERATIONS EXECUTIVE COMMITTEE
- Philip Beale
- Alison Brand
- Alain Davis
- Martin Stockler
- Candace Carter
- John Andrews
- Peey Siy Kok
- Elisa Carolus
- Alison Evans

### CONSUMER AND COMMUNITY COMMITTEE
- Helen O’Neill (Chair to April 2018 – 10 years service)
- Penny Stoyles (CCC member to April 2018 – 10 years service)
- Wanda Lawson (Chair of Consumer Research Panel from April 2018)
- Cheryl Walker
- Rhonda Beach
- Lisa Finucane
- Leonie McQuire
- Fiona Price
- Kathryn Comerwaile

### QUALITY ASSURANCE COMMITTEE
- Pearly Khaw (Chair)
- Alison Brand
- Michelle Harrison
- Belinda Egan
- Alison Hadley
- Philip Chan
- Maheesh Iddawela
- Ganendra Raj Kader Ali Mohan

### ANZGOG RESEARCH MANAGEMENT GROUP
- Michael Friedlander AM (Chair)
- Sue Brew
- Philip Beale
- Alison Brand
- Bo Gao
- Chee Khiong Lee
- Anna de Fazio
- Michelle Wilson
- Karen Livingstone
- David Bowtell
- Clare Scott
- Linda Mileshkin
- George Au-Yeung
- Tarek Meniawy

### OVASIS STEERING COMMITTEE
- Michael Friedlander AM (Chair)
- Sue Brew
- Philip Beale
- Alison Brand
- Pearly Khaw
- Rachel Delahunty

### UTERINE TUMOUR GROUP
- Diana Adams (Chair until February)
- Yoland Antill (Chair from April 2018)
- Rhonda Farrell (Co-Chair from April 2018)
- Elizabeth Barnes
- Cheryl Waller
- Peey Siy Kok
- Sinivas Kondalakramy-Chananesan
- Andrea Garrett
- Amanda Spurle
- Eva Baxter
- Pamela Pollock
- Ganessan Kichenadasse
- Mahesh Iddawela
- Pearly Khaw
- Rachel Delahunty

### STUDY COORDINATORS COMMITTEE
- Sue Brew (Chair)
- David Cannan
- Donna Long
- Kathryn Jenkins
- Belinda Egan
- Elizabeth Wardrop
- Jenny Campbell
- Meghan Leigh
- Vanessa Taylor
- Melissa Groom
- Joanne Youd

### ANZGOG RESEARCH MANAGEMENT GROUP
- Philip Beale
- Alison Brand
- Alain Davis
- Michelle Vaughan
- Alison Evans
- Tracey Meares

### STAFF AUDIT RISK COMMITTEE
- David Rogers
- Philip Beale
- Rachael Sutton

### NOMINATIONS COMMITTEE
- Philip Beale
- Alison Brand
- Michael Friedlander AM
- Carol Johnson
- Danny Rishcin

### ANZGOG CTC OPERATIONS EXECUTIVE COMMITTEE
- Philip Beale
- Alison Brand
- Alain Davis
- Martin Stockler
- Candace Carter
- John Andrews
- Peey Siy Kok
- Elisa Carolus
- Alison Evans

### CONSUMER AND COMMUNITY COMMITTEE
- Helen O’Neill (Chair to April 2018 – 10 years service)
- Penny Stoyles (CCC member to April 2018 – 10 years service)
- Wanda Lawson (Chair of Consumer Research Panel from April 2018)
- Cheryl Walker
- Rhonda Beach
- Lisa Finucane
- Leonie McQuire
- Fiona Price
- Kathryn Comerwaile

### QUALITY ASSURANCE COMMITTEE
- Pearly Khaw (Chair)
- Alison Brand
- Michelle Harrison
- Belinda Egan
- Alison Hadley
- Philip Chan
- Maheesh Iddawela
- Ganendra Raj Kader Ali Mohan

### ANZGOG RESEARCH MANAGEMENT GROUP
- Michael Friedlander AM (Chair)
- Sue Brew
- Philip Beale
- Alison Brand
- Bo Gao
- Chee Khiong Lee
- Anna de Fazio
- Michelle Wilson
- Karen Livingstone
- David Bowtell
- Clare Scott
- Linda Mileshkin
- George Au-Yeung
- Tarek Meniawy

### OVASIS STEERING COMMITTEE
- Michael Friedlander AM (Chair)
- Sue Brew
- Philip Beale
- Alison Brand
- Pearly Khaw
- Rachel Delahunty
Our Structure

ANZGOG Members

Physicians
Surgeons
Nurses
Specialist Researchers
Data Managers

50 Hospitals across Australia & New Zealand

Women with Gynaecological Cancer & their Families

Board of Directors

Research Advisory
Quality Assurance
Study Coordination
Consumer Advisory
Scientific Meetings
Nominations

Research Management Group

Operating Centre
BACT
Peter MacCallum Cancer Centre

Collaborative Coordinating Centre
NHMRC CLINICAL TRIALS CENTRE
University of Sydney

Executive Management Team

Research
Fundraising
Information
Administration

Other Operating Centres
**Government grant support**

ANZGOG and the University of Sydney NHMRC Clinical Trials Centre (CTC) have a collaborative agreement together which supports the development and operation of many ANZGOG clinical trials.

Government grant funding for the benefit of ANZGOG clinical trials projects is administered by the University of Sydney and is received annually to support research activities.

In 2018 $1,921,887 in government grants and other funding was achieved via the University of Sydney for ANZGOG’s research, bringing the total since 2002 to $19,543,217.

These funds are not reported in the ANZGOG Annual Financial Statements but are received in addition to our other fundraising achievements.

**Research project funding**

Significant trial funds received and administered by the University of Sydney in 2018 were:

<table>
<thead>
<tr>
<th>Project</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solace2</td>
<td>$425,000</td>
</tr>
<tr>
<td>STICs &amp; STONEs</td>
<td>$311,831</td>
</tr>
<tr>
<td>PHAEDRA</td>
<td>$185,400</td>
</tr>
<tr>
<td>STATEC</td>
<td>$232,649</td>
</tr>
</tbody>
</table>

**Support for clinical trials**

The Cancer Australia Support for Cancer Clinical Trials Program, which is shared 50:50 with the NHMRC Clinical Trials Centre, provides $230,000 annually and this figure is included in income statements.

ANZGOG was awarded the Cancer Australia Support for Clinical Trials Program grant in 2018 for a further 3 years from 2018 to 2021.

**Philanthropic and other grants**

Funds were received in 2018 for a number of new research and education initiatives. They are held in non-current liabilities until expensed. At 30 June 2018 these were:

<table>
<thead>
<tr>
<th>Initiative</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>OASIS Initiative Research Projects</td>
<td>$425,000</td>
</tr>
<tr>
<td>Survivors Teaching Students®</td>
<td>$311,831</td>
</tr>
</tbody>
</table>

In addition in 2018, the Rose Varga Bequest was given to benefit ovarian cancer research conducted under the OASIS Initiative and is held in ANZGOG Reserves for future use on OASIS projects.
Financial Statements

(abbreviated)

<table>
<thead>
<tr>
<th>Revenue</th>
<th>2018 $</th>
<th>2017 $</th>
</tr>
</thead>
<tbody>
<tr>
<td>Government grant</td>
<td>546,731</td>
<td>372,765</td>
</tr>
<tr>
<td>Trial projects</td>
<td>458,660</td>
<td>274,484</td>
</tr>
<tr>
<td>Philanthropic grant</td>
<td>107,808</td>
<td>34,430</td>
</tr>
<tr>
<td>Fundraising activities</td>
<td>2,533,997</td>
<td>806,179</td>
</tr>
<tr>
<td>Corporate sponsorship</td>
<td>193,191</td>
<td>208,927</td>
</tr>
<tr>
<td>Annual Scientific Meeting conference</td>
<td>124,691</td>
<td>137,734</td>
</tr>
<tr>
<td>Interest income</td>
<td>26,533</td>
<td>13,663</td>
</tr>
<tr>
<td>Dividend income</td>
<td>35,000</td>
<td>–</td>
</tr>
<tr>
<td>Rental income</td>
<td>35,000</td>
<td>33,008</td>
</tr>
<tr>
<td>Gain on sale of property</td>
<td>35,000</td>
<td>–</td>
</tr>
</tbody>
</table>

Total income                                   | **4,098,863** | **1,892,548** |

Annual Income with Surplus

## Financial Statements

*(abbreviated)*

### Balance Sheet

<table>
<thead>
<tr>
<th>Financial Statement</th>
<th>2018 ($)</th>
<th>2017 ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>2,684,895</td>
<td>3,783,386</td>
</tr>
<tr>
<td>Trade and other receivables</td>
<td>573,552</td>
<td>462,693</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td>3,258,447</td>
<td>4,246,079</td>
</tr>
<tr>
<td><strong>Non-current assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plant and equipment</td>
<td>13,606</td>
<td>8,379</td>
</tr>
<tr>
<td>Intangible assets</td>
<td>10,816</td>
<td>-</td>
</tr>
<tr>
<td>Available-for-sale financial assets</td>
<td>3,158,760</td>
<td>177,780</td>
</tr>
<tr>
<td>Investment properties</td>
<td>230,000</td>
<td>570,000</td>
</tr>
<tr>
<td><strong>Total non-current assets</strong></td>
<td>3,413,182</td>
<td>756,159</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>6,671,629</td>
<td>5,002,238</td>
</tr>
<tr>
<td><strong>Current liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade and other payables</td>
<td>1,377,340</td>
<td>1,527,976</td>
</tr>
<tr>
<td>Employee benefits</td>
<td>64,604</td>
<td>50,108</td>
</tr>
<tr>
<td><strong>Total current liabilities</strong></td>
<td>1,441,944</td>
<td>1,578,084</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>1,441,944</td>
<td>1,578,084</td>
</tr>
<tr>
<td><strong>Net assets</strong></td>
<td>5,229,685</td>
<td>3,424,154</td>
</tr>
<tr>
<td><strong>Equity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Available for sale financial assets reserve</td>
<td>9,701</td>
<td>3,665</td>
</tr>
<tr>
<td>New Research Fund reserve</td>
<td>499,350</td>
<td>547,983</td>
</tr>
<tr>
<td>Beneficiary Fund reserve</td>
<td>224,053</td>
<td>227,989</td>
</tr>
<tr>
<td>OASIS Initiative reserve</td>
<td>2,085,933</td>
<td>-</td>
</tr>
<tr>
<td>Retained surplus</td>
<td>2,410,648</td>
<td>2,644,517</td>
</tr>
<tr>
<td><strong>Total equity</strong></td>
<td>5,229,685</td>
<td>3,424,154</td>
</tr>
</tbody>
</table>

### Equity

![Equity Graph](https://www.acnc.gov.au/charity/anzgog)

## Financial Statements

(abbreviated)

### CASH FLOWS

<table>
<thead>
<tr>
<th>Description</th>
<th>2018 $</th>
<th>2017 $</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Receipts from grants</td>
<td>792,919</td>
<td>1,472,196</td>
</tr>
<tr>
<td>Receipts from donations</td>
<td>2,430,048</td>
<td>671,213</td>
</tr>
<tr>
<td>Receipts from sponsorships, Annual Scientific Meeting conference,</td>
<td>442,593</td>
<td>349,170</td>
</tr>
<tr>
<td>insurance recoveries and other revenue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Payments to suppliers and employees</td>
<td>(2,209,666)</td>
<td>(1,453,077)</td>
</tr>
<tr>
<td><strong>Net cash inflow from operating activities</strong></td>
<td>1,455,894</td>
<td>1,039,502</td>
</tr>
<tr>
<td><strong>Cash flows from investing activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Payments for purchase of plant &amp; equipment</td>
<td>(11,578)</td>
<td>(2,263)</td>
</tr>
<tr>
<td>Payments for purchase of intangible assets</td>
<td>(10,816)</td>
<td></td>
</tr>
<tr>
<td>Purchase of investments</td>
<td>(2,974,945)</td>
<td>-</td>
</tr>
<tr>
<td>Dividend income from investments</td>
<td>54,219</td>
<td>11,358</td>
</tr>
<tr>
<td>Interest received</td>
<td>25,533</td>
<td>13,663</td>
</tr>
<tr>
<td>Cash received on sale of investment property</td>
<td>362,202</td>
<td></td>
</tr>
<tr>
<td><strong>Net cash (outflow)/inflow from investing activities</strong></td>
<td>(2,554,385)</td>
<td>22,758</td>
</tr>
<tr>
<td><strong>Net (decrease)/increase in cash and cash equivalents</strong></td>
<td>(1,098,491)</td>
<td>1,062,260</td>
</tr>
<tr>
<td>Cash and cash equivalents at the beginning of the year</td>
<td>3,783,386</td>
<td>1,631,126</td>
</tr>
<tr>
<td>Cash acquired on amalgamation</td>
<td>-</td>
<td>1,090,000</td>
</tr>
<tr>
<td><strong>Cash and cash equivalents at the end of the year</strong></td>
<td>2,684,895</td>
<td>3,783,386</td>
</tr>
</tbody>
</table>

INDEPENDENT AUDITOR’S REPORT

To the members of Australia New Zealand Gynaecological Oncology Group


Qualified opinion

We have audited the financial report of Australia New Zealand Gynaecological Oncology Group (ANZGOG), which comprises the statement of financial position as at 30 June 2018, the statement of profit or loss and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies, and the directors’ declaration.

In our opinion, except for the effects of the matter described in the Basis for qualified opinion section of our report, the accompanying financial report of ANZGOG, is in accordance with Division 60 of the Australian Charities and Not-for-profits Commission Act 2012, including:

(i) Giving a true and fair view of the company’s financial position as at 30 June 2018 and of its financial performance for the year then ended; and

(ii) Complying with Australian Accounting Standards - Reduced Disclosure Requirements and Division 60 of the Australian Charities and Not-for-profits Commission Regulation 2013.

Basis for qualified opinion

Cash donations are a significant source of fundraising revenue for ANZGOG. ANZGOG has determined that it is impracticable to establish control over the collection of cash donations prior to entry into its financial records. Accordingly, as the evidence available to us regarding fundraising revenue from this source was limited, our audit procedures with respect to cash donations had to be restricted to the amounts recorded in the financial records amounting to $42,080.62. We therefore are unable to express an opinion whether cash donations for ANZGOG recorded are complete.

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the Financial Report section of our report. We are independent of the registered entity in accordance with the auditor independence requirements of the Australian Charities and Not-for-profits Commission Act 2012 (ACNC Act) and the ethical requirements of the Accounting Professional and Ethical Standards Board’s APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Other information

Those charged with governance are responsible for the other information. The other information obtained at the date of this auditor’s report is information included in the ANZGOG’s annual report, but does not include the financial report and our auditor’s report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information obtained prior to the date of this auditor’s report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Directors’ Responsibility for the Financial Report

The directors of the company are responsible for the preparation and fair presentation of the financial report in accordance with Australian Accounting Standards – Reduced Disclosure Requirements and the ACNC Act, and for such internal control as the directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

In preparing the financial report, directors are responsible for assessing the company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the responsible entities either intends to liquidate the registered entity or to cease operations, or has no realistic alternative but to do so.

The directors are responsible for overseeing the company’s financial reporting process.

Auditor’s responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.


This description forms part of our auditor’s report.

BDO East Coast Partnership

Paul Cheeseman
Partner
Sydney, 27 September 2018

The Australian Business Number (ABN) is 69 138 649 028.
The Australian Company Number (ACN) is 138 649 028.
The Australian New Zealand Gynaecological Oncology Group is an Australian public company limited by guarantee trading under the name Australia New Zealand Gynaecological Oncology Group or ANZGOG.

ANZGOG is registered for charitable fundraising in all States and Territories of Australia:

- Western Australia – License No. 21334
- Queensland – Registration No. CH2213
- New South Wales – Charitable Fundraising No. CFN/21451
- South Australia – License No. CCP1765
- Tasmania – File No. F1A-331
- Australian Capital Territory – License No. 19000383
- Victoria – Registration No. 11419.13
- Northern Territory – Reference No. 2010-4117

ANZGOG is a Health Promotion Charity.
ANZGOG is endorsed as a deductible gift recipient under Section 30-15 of the Income Tax Assessment Act 1997.
ANZGOG operates under a comprehensive legislative environment, including the following state and federal laws:

**STATE**
- Annual Holidays Act 1944 (NSW)
- Anti-discrimination Act 1977 (NSW)
- Charitable Fundraising Act 1991 (NSW)
- Charitable Trusts Act 1993 (NSW)
- Crimes Act 1900 (NSW)
- Fair Trading Act 1987 (NSW)
- Health Records and Information Privacy Act 2002 (NSW)
- Long Service Leave Act 1955 (NSW)
- Public Holidays Act 2010 (NSW)
- Work Health and Safety Act 2011 (NSW)
- Workers Compensation Act 1987 (NSW)
- Workplace Injury Management and Workers Compensation Act 1998 (NSW)

**FEDERAL**
- A New Tax System (Goods and Services) Act 1999
- Age Discrimination Act 2004
- Australian Charities and Not-for-Profit Commission Act 2012
- Charities Act 2013
- Competition and Consumer Act 2010
- Corporations Act 2001
- Defamation Act 2005
- Disability Discrimination Act 1992
- Fair Work Act 2009
- Fringe Benefits Tax Assessment Act 1986
- Income Tax Assessment Act 1997
- Privacy Act 1988
- Racial Discrimination Act 1975
- Sex Discrimination Act 1984
- Workplace Gender Equality Act 2012
ANZGOG’s Head Office:
Australia New Zealand Gynaecological Oncology Group
Level 6, Chris O’Brien Lifehouse
119-143 Missenden Road, CAMPERDOWN NSW 2050

POSTAL: Locked Bag M45, Missenden Road, NSW 2050
Phone: +61 2 8071 4880
Fax: +61 2 8071 4888
Email: admin@anzgog.org.au

ANZGOG’s Melbourne Office:
Women’s Cancer Foundation
Suite 122, Level 1,
1 Queens Road, MELBOURNE VIC 3004

Phone: +61 3 9867 3515
Email: contact@anzgog.org.au

SaveTheBox
GoforGynae
womenscancerfoundation
@savetheboxnow
@anzgog